Scinovex
Subscribe
J

Jedd D. Wolchok

Cornell UniversityORCID https://orcid.org/0000-0001-6718-2222
h-index
—
Publications
—
Citations
—
i10-index
—
Impact (2-yr)
—

Top Publications

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
New England Journal of Medicine201015,037 citations
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
New England Journal of Medicine20158,055 citations
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Science20157,864 citations
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Nature Genetics20194,300 citations
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET
Nature Medicine20123,679 citations
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Journal of Clinical Oncology20183,616 citations
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Clinical Cancer Research20093,204 citationsFirst authorCorresponding
Immune Checkpoint Blockade in Cancer Therapy
Journal of Clinical Oncology20152,706 citations
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
Science Translational Medicine20162,413 citationsCorresponding
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
The Lancet Oncology20172,334 citations
Antibody therapy of cancer
Nature reviews. Cancer20122,121 citations
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
Journal of Clinical Oncology20152,105 citations
RECIST 1.1—Update and clarification: From the RECIST committee
European Journal of Cancer20161,839 citations
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
The Lancet Oncology20151,554 citations
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
Annals of Oncology20151,449 citations
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
The Lancet Oncology20181,386 citations
Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
Annals of Oncology2019928 citations
Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy
Science Translational Medicine2014696 citationsCorresponding
Classification of current anticancer immunotherapies
Oncotarget2014467 citations
Jedd D. Wolchok · Scinovex